Esperion Therapeutics (ESPR) Receivables - Net (2020 - 2025)
Esperion Therapeutics (ESPR) has disclosed Receivables - Net for 6 consecutive years, with $140.2 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Receivables - Net rose 74.93% year-over-year to $140.2 million, compared with a TTM value of $140.2 million through Dec 2025, up 74.93%, and an annual FY2025 reading of $140.2 million, up 74.93% over the prior year.
- Receivables - Net was $140.2 million for Q4 2025 at Esperion Therapeutics, up from $119.0 million in the prior quarter.
- Across five years, Receivables - Net topped out at $140.2 million in Q4 2025 and bottomed at $17.3 million in Q1 2021.
- Average Receivables - Net over 5 years is $54.1 million, with a median of $41.7 million recorded in 2023.
- The sharpest move saw Receivables - Net surged 85.13% in 2021, then grew 27.41% in 2022.
- Year by year, Receivables - Net stood at $22.9 million in 2021, then soared by 47.07% to $33.7 million in 2022, then skyrocketed by 43.78% to $48.5 million in 2023, then soared by 65.26% to $80.1 million in 2024, then skyrocketed by 74.93% to $140.2 million in 2025.
- Business Quant data shows Receivables - Net for ESPR at $140.2 million in Q4 2025, $119.0 million in Q3 2025, and $107.7 million in Q2 2025.